ATE507836T1 - 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) - Google Patents

2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)

Info

Publication number
ATE507836T1
ATE507836T1 AT05824840T AT05824840T ATE507836T1 AT E507836 T1 ATE507836 T1 AT E507836T1 AT 05824840 T AT05824840 T AT 05824840T AT 05824840 T AT05824840 T AT 05824840T AT E507836 T1 ATE507836 T1 AT E507836T1
Authority
AT
Austria
Prior art keywords
heparin
desulfated
medicament
desulfated heparin
hit
Prior art date
Application number
AT05824840T
Other languages
German (de)
English (en)
Inventor
Jeanine Walenga
Thomas Kennedy
Original Assignee
Paringenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paringenix Inc filed Critical Paringenix Inc
Application granted granted Critical
Publication of ATE507836T1 publication Critical patent/ATE507836T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10Heparin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT05824840T 2004-10-27 2005-10-26 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) ATE507836T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/974,566 US7468358B2 (en) 2004-06-16 2004-10-27 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
PCT/US2005/039011 WO2006047755A2 (en) 2004-10-27 2005-10-26 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome

Publications (1)

Publication Number Publication Date
ATE507836T1 true ATE507836T1 (de) 2011-05-15

Family

ID=36228513

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05824840T ATE507836T1 (de) 2004-10-27 2005-10-26 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)

Country Status (9)

Country Link
US (1) US7468358B2 (enExample)
EP (1) EP1807095B1 (enExample)
JP (1) JP2008518090A (enExample)
AT (1) ATE507836T1 (enExample)
AU (1) AU2005299568A1 (enExample)
CA (1) CA2585640C (enExample)
DE (1) DE602005027883D1 (enExample)
ES (1) ES2366342T3 (enExample)
WO (1) WO2006047755A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20090054374A1 (en) * 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
WO2009117677A2 (en) * 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
US8288515B2 (en) 2009-07-31 2012-10-16 Reliable Biopharmaceutical Corporation Process for preparing Fondaparinux sodium and intermediates useful in the synthesis thereof
US8420790B2 (en) 2009-10-30 2013-04-16 Reliable Biopharmaceutical Corporation Efficient and scalable process for the manufacture of Fondaparinux sodium
DK3144325T3 (da) * 2010-09-14 2021-01-25 Univ Miyazaki Heparin med høj renhed og fremstillingsfremgangsmåde dertil
NZ611316A (en) * 2010-12-01 2014-12-24 Univ Australian Histone inhibition
WO2013016181A1 (en) * 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
CA2862606C (en) 2012-02-02 2020-08-25 Reliable Biopharmaceutical Corporation An efficient and scalable process for the manufacture of fondaparinux sodium
LT2846809T (lt) * 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
AU2016234916A1 (en) * 2012-05-09 2016-11-17 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
EP3265828B1 (en) 2015-03-03 2021-04-21 Laboratory Corporation of America Holdings Methods and systems for measuring serotonin in a sample
WO2019236453A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
GB202006960D0 (en) * 2020-05-12 2020-06-24 Aplagon Oy Therapeutic

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
EP0651645B1 (en) * 1992-07-24 2002-02-27 Thomas P. Kennedy Medicament for inhibiting neutrophil elastase and cathepsin g
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
DE69930419T2 (de) 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
AU763042B2 (en) 1999-09-13 2003-07-10 Charlotte-Mecklenburg Hospital Authority Method of inhibiting NF-kappaB with heparin
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US20080207895A1 (en) 2002-11-27 2008-08-28 Rosenberg Robert D Methods for synthesizing polysaccharides
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome

Also Published As

Publication number Publication date
CA2585640A1 (en) 2006-05-04
EP1807095A2 (en) 2007-07-18
EP1807095B1 (en) 2011-05-04
WO2006047755A2 (en) 2006-05-04
ES2366342T3 (es) 2011-10-19
JP2008518090A (ja) 2008-05-29
WO2006047755A3 (en) 2007-02-01
DE602005027883D1 (de) 2011-06-16
EP1807095A4 (en) 2008-08-27
US7468358B2 (en) 2008-12-23
AU2005299568A1 (en) 2006-05-04
US20070123489A1 (en) 2007-05-31
CA2585640C (en) 2012-01-10

Similar Documents

Publication Publication Date Title
ATE507836T1 (de) 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)
Gray et al. The anticoagulant and antithrombotic mechanisms of heparin
DE50310724D1 (de) Herstellung von suspension hydrophober oxidpartikel
WO2006023397A3 (en) Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
DE69928219D1 (de) Lipasehemmende polymere
ATE478867T1 (de) Substituierte quinazolinone verbindungen
ATE523212T1 (de) Synthetische mehrschichtige hornhautstrukturen mit kollagen-fasern
BR9608330A (pt) Copolìmero em bloco heterotelequélico e um método para a produção do mesmo.
BR0010380A (pt) Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos
UA100378C2 (uk) Полімерна композиція, спосіб її виготовлення, виріб, спосіб його виготовлення та спосіб формування, застосування, спосіб підвищення швидкості текучості розплаву суміші та спосіб зменшення технологічного циклу формування виробу
BR8304973A (pt) Mistura de polimero compativel
DE602006008985D1 (de) Zusammensetzung enthaltend oligosaccharide als lösliche ballaststoffe zur verwendung gegen muskelschwund
Xu et al. Heparin: an intervenor in cell communication
JP2008518090A5 (enExample)
DE502007003544D1 (de) Verfahren zur herstellung von superabsorbern
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
BRPI0416088A (pt) composição, sistema, e método de tratar condições tais como calcificação vascular
MX2025002806A (es) Combinaciones terapeuticas para los trastornos del movimiento
CY1105020T1 (el) Υποκαταστατες διαζεπανες
EA200802307A1 (ru) Бинарные смеси гиалуроновой кислоты и их терапевтическое применение
BR112021010615A2 (pt) Clazakizumab no tratamento de rejeição crônica de transplante de órgãos mediada por anticorpos
IL165808A0 (en) Low molecular weight k5-n,o-oversulfated polysaccharide process for the preparation thereof and pharmaceutical compositions containing the same
DK1511466T3 (da) Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD
WO2009137899A3 (en) Sulfated galactans with antithrombotic activity, pharmaceutical composition, method for treating or prophylaxis of arterial or venous thrombosis, method of extraction and use thereof
BR0313613A (pt) Variantes do principal alérgeno phl p 1 de capim-timóteo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties